解码雌激素受体和GPER生物学:在ERα阳性乳腺癌中的结构见解和治疗进展
Taniya Saha1, Kiven Erique Lukong1
1Department of Biochemistry, Microbiology, and Immunology, University of Saskatchewan, Saskatoon, SK, Canada.
Frontiers in oncology
|July 11, 2025
概括
在ERα阳性乳腺癌中激活ESR1突变驱动内分泌治疗耐药性. 针对这些突变和GPER提供了一个有希望的策略,以克服转移性乳腺癌的治疗挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 内分泌学 在内分泌学.
背景情况:
- 雌激素受体 (ERα,ERβ) 和GPER是ERα阳性乳腺癌的关键驱动因素.
- 内分泌疗法 (ET) 是标准的治疗方法,但获得的耐药性是一个主要的挑战.
- 激活ESR1突变在耐药转移性乳腺癌中很常见,导致连接体独立的ERα激活.
研究的目的:
- 审查内分泌治疗耐药性的ERα和ESR1突变的结构和功能方面.
- 探索GPER介导信号在他莫西芬耐药性中的作用.
- 突出针对ERα突变体和GPER克服抗性的新型治疗策略.
主要方法:
- 对ERα,ESR1突变和GPER的结构和功能研究的文献综述.
- 对ERα阳性乳腺癌内分泌治疗耐药性背后的机制的分析.
- 综合关于下一代治疗方法的当前研究.
主要成果:
- ESR1突变使ERα稳定在活性构造中,促进耐药性.
- GPER信号传递有助于抵抗,通常由当前疗法激活.
- 了解这些机制对于开发有针对性的疗法至关重要.
结论:
- 针对ERα突变和GPER,可能提供一种针对内分泌疗法耐药性的综合策略.
- 下一代疗法为转移性ERα阳性乳腺癌的改善结果提供了希望.
- 对这些途径的进一步研究对于临床进步至关重要.
相关概念视频
G Protein-coupled Receptors
13.5K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.5K
Mitogens and the Cell Cycle
6.9K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Transducer Mechanism: Nuclear Receptors
1.7K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.8K
Transducer Mechanism: G Protein–Coupled Receptors
2.5K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
2.5K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


